TY -的T1 -机械血栓切除术后的不良预后的预测成功再通(p1.3 - 033) JF -神经学乔-神经学六世- 92 - 15补充SP - p1.3 - 033 AU -穆罕默德Anadani盟穆罕默德Orabi AU -阿里Alaw首页ieh盟Nitin Goyal盟Fnu Abhi Pandhi AU -亨特米切尔盟安德烈Alexandrov AU -麦尔Ilko盟Marios-Nikos Psychogios AU - Ovais Inamullah AU - Shareena拉赫曼盟Christa史伟莎AU -沙拉Keyrouz AU -詹姆斯·贾尔斯AU -米歇尔·艾伦AU -阿卡什Kansagra AU -沃尔夫斯泰西AU -彼得菅直人AU -法比奥Nascimento AU -本杰明血淋淋的AU -皮埃尔·德·马里尼AU -亚历杭德罗Spiotta Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p1.3 - 033. -文摘N2 -目的:研究贫困的预测结果在接受机械血栓切除术的患者急性中风。背景:尽管与现代血栓切除术设备再通率高、功能独立只有实现约50%的病人。在这项研究中,我们旨在调查可怜的预测结果在病人机械血栓切除术成功再通。设计/方法:多中心的国际数据库从9血栓切除术中心前瞻性收集。患者包括如果他们遇到前循环大血管闭塞(LVO)和接受机械血栓切除术(MT)成功再通。额外的标准是阿尔伯塔省中风项目早期CT扫描(方面)得分6,基线改良Rankin规模(夫人)0 - 2。主要结果是90天的夫人3 - 6。多元逻辑回归是用来识别预测的结果。结果:共有1077名患者包括在这项研究中,528名(49%)不良结果(3 - 6)夫人在90天。良好的结果相比,穷人结果组年龄(年龄意味着±SD, 71±14 vs 65±14年;术;0.001),有更高的入学署(平均数±标准差;18±6 vs 14±6; p=0.001), and lower ASPECT score (median (IQR);8 (3) vs. 9(2); p <0.001). With respect to procedural variables, modified Tissue in Cerebral Infarction score (mTICI) 2c/3 was less common in poor outcome group (59% vs. 67%; p= 0.006). Antihypertensive medications were used more frequently in poor outcome group (60% vs. 49%, p =0.001). Symptomatic intracerebral hemorrhage (sICH) was more frequent in poor outcome group (8% vs. 0.6%; p<0.0001). In addition, acute kidney injury was more common in poor outcome group (13% vs. 7% p <0.001). On multivariate analysis, age, admission NIHSS, ASPECT score, sICH, AKI, antihypertensive use, and final mTICI score emerged as predictors of poor outcome.Conclusions: Older age, higher admission NIHSS, lower ASPECT score, symptomatic intracerebral hemorrhage, antihypertensive use and mTICI 2b were associated with poor outcome after successful recanalization.Disclosure: Dr. Anadani has nothing to disclose. Dr. Orabi has nothing to disclose. Dr. Alawieh has nothing to disclose. Dr. Goyal has nothing to disclose. Dr. Pandhi has nothing to disclose. Dr. Mitchell has nothing to disclose. Dr. Alexandrov has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech, Inc, Cerevast Medical, Siemens. Dr. Maier has nothing to disclose. Dr. Psychogios has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Siemens Healthineers. Dr. Psychogios has received research support from Siemens Medical Solutions. Dr. Inamullah has nothing to disclose. Dr. Rahman has nothing to disclose. Dr. Swisher has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai and UCB. Dr. Keyrouz has nothing to disclose. Dr. Giles has nothing to disclose. Dr. Allen has nothing to disclose. Dr. Kansagra has nothing to disclose. Dr. Wolfe has nothing to disclose. Dr. Kan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consultant for Stryker and Medtronic. Dr. Kan holds stock and/or stock options in Inneuroco which sponsored research in which Dr. Kan was involved as an investigator. . Dr. Nascimento has nothing to disclose. Dr. Gory has nothing to disclose. Dr. De Marini has nothing to disclose. Dr. Spiotta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Penumbra, Pulsar Vascular, Microvention, Stryker. ER -